ライフサイエンスコーパス: organ transplantation

1 quired immune deficiency states (e.g., after organ transplantation).

2 se of weight limits (ie, orthopedic surgery, organ transplantation).

3 treating hypoxic-ischemic human diseases and organ transplantation.

4 ted rejection and graft loss after all solid organ transplantation.

5 lograft survival and unmet clinical needs in organ transplantation.

6 he main obstacle in the long-term success of organ transplantation.

7 risk of skin cancer, particularly SCC, after organ transplantation.

8 A) is recommended in patients awaiting solid organ transplantation.

9 immunodeficiency virus (HIV)-caused AIDS and organ transplantation.

10 ental illness (SMI) a significant concern in organ transplantation.

11 enge limiting allograft survival after solid organ transplantation.

12 in myocardial infarction, stroke, and solid organ transplantation.

13 incidence of cancer is increased after solid organ transplantation.

14 gnificant role in graft survival after solid organ transplantation.

15 ytomegalovirus (CMV) replication after solid organ transplantation.

16 r controlling antibody-mediated rejection in organ transplantation.

17 ation, remains the major problem in clinical organ transplantation.

18 olved in post-I/R injuries as observed after organ transplantation.

19 infrequent but serious complication of solid organ transplantation.

20 been widely used to prevent rejection after organ transplantation.

21 ion of nitric oxide inhibition reduce IRI in organ transplantation.

22 Diarrhea is a frequent complication of solid organ transplantation.

23 t survival is a major challenge facing solid organ transplantation.

24 iseases and to prevent graft rejection after organ transplantation.

25 t important cutaneous complication following organ transplantation.

26 allograft injury and improve the outcomes of organ transplantation.

27 gs is one of the key research goals in solid organ transplantation.

28 ut allergy has been reported following solid organ transplantation.

29 s to allografts represent a major barrier in organ transplantation.

30 atopoiesis and to induce tolerance for solid organ transplantation.

31 ajor source of morbidity and mortality after organ transplantation.

32 DQ antigens and antibodies are evaluated for organ transplantation.

33 mpromised patients, particularly after solid organ transplantation.

34 he case of therapeutic immunosuppression for organ transplantation.

35 ch as IPoC can improve the outcomes of human organ transplantation.

36 therapeutic agents to improve the outcome of organ transplantation.

37 and immune control of replication post-solid organ transplantation.

38 e effect of aging and the immune response to organ transplantation.

39 hodology to reposition FDA approved drugs in organ transplantation.

40 phic variation in CMV management after solid organ transplantation.

41 tation monitoring of HLA antibodies in solid organ transplantation.

42 and substance abuse in the context of solid-organ transplantation.

43 cause of mortality and morbidity after solid organ transplantation.

44 d can mediate immune tolerance to subsequent organ transplantation.

45 imary cause of long-term graft failure after organ transplantation.

46 osis (ALS) are a viable source of tissue for organ transplantation.

47 HHV) are exacerbated by immunosuppression in organ transplantation.

48 s, it has received little attention in solid organ transplantation.

49 may also be associated with PRES after solid organ transplantation.

50 tis and can be transmitted through tissue or organ transplantation.

51 l research, tissue engineering research, and organ transplantation.

52 ansplantation, autoimmune disease, and solid organ transplantation.

53 (UNOS) and outcomes were compared to single-organ transplantation.

54 ly applicable refinement of Treg therapy for organ transplantation.

55 g therapy and their therapeutic potential in organ transplantation.

56 Skin cancer is a frequent complication of organ transplantation.

57 de in improving short-term outcomes in solid organ transplantation.

58 timal agent for tolerance induction in human organ transplantation.

59 s a well-recognized complication after solid-organ transplantation.

60 have raised concerns about medical errors in organ transplantation.

61 a common opportunistic infection after solid organ transplantation.

62 ased age, white race, male sex, and thoracic organ transplantation.

63 (IRI) remains unresolved problem in clinical organ transplantation.

64 he use of CD154 as a peripheral biomarker in organ transplantation.

65 ward personalized and predictive medicine in organ transplantation.

66 ut challenging type of rejection after solid organ transplantation.

67 d outcomes of colectomy for CDAD after solid organ transplantation.

68 d cancer, and to prevent rejection following organ transplantation.

69 eal transplantation is the most common solid organ transplantation.

70 s the most common malignancy occurring after organ transplantation.

71 improve chronic CNI nephrotoxicity in solid organ transplantation.

72 ion of cytomegalovirus (CMV) is essential in organ transplantation.

73 ne of the most common infections after solid organ transplantation.

74 n the cellular and humoral response in solid organ transplantation.

75 oses of immunosuppression is a major goal in organ transplantation.

76 rder (PTLD) is a major complication of solid-organ transplantation.

77 pediatric with EBV (+) PTLD following solid-organ transplantation.

78 s cell biology, tissue engineering, and cell/organ transplantation.

79 als as a potential therapy in cell and solid organ transplantation.

80 henolate sodium, and it is widely used after organ transplantation.

81 matching improves graft survival rates after organ transplantation.

82 25-30 times greater in CF patients after an organ transplantation.

83 ng the organ supply/demand mismatch in solid organ transplantation.

84 s in HLA antibody responses and matching for organ transplantation.

85 regarding the use of social media to foster organ transplantation.

86 g those associated with bone marrow or solid organ transplantation.

87 ns of reducing allograft rejection following organ transplantation.

88 les in ocular surface immunity and allogenic organ transplantation.

89 s and opportunities in contemporary clinical organ transplantation.

90 s and solutions to the current challenges in organ transplantation.

91 ent and its effect on the immune response to organ transplantation.

92 potential uses of nanotechnology in cell and organ transplantation.

93 fted tissues are the major reason for failed organ transplantation.

94 , prenatal diagnosis, infectious diseases or organ transplantation.

95 ns of this novel MPS classification in solid organ transplantation.

96 tions for this malignancy-tumor resection or organ transplantation.

97 patients who are not considered eligible for organ transplantation.

98 outcomes associated with smoking after solid organ transplantation.

99 HHV-8)-related disease described after solid organ transplantation.

100 fter allogeneic hematopoietic cell and solid organ transplantation.

101 tious diseases, and it has also been used in organ transplantation.

102 ful monitoring tool in cancer, pregnancy and organ transplantation.

103 provides an alternative pathway to deceased organ transplantation.

104 cess of ischemia-reperfusion injury (IRI) in organ transplantation.

105 itions but has only recently been applied to organ transplantation.

106 is improving long-term outcomes after solid organ transplantation.

107 tems have successfully been applied in solid organ transplantations.

108 g transplantation are the lowest among solid organ transplantations.

109 50%, which is far behind that of other solid organ transplantations.

110 e prospective multicenter Clinical Trials in Organ Transplantation-04 study.

111 The Clinical Trials in Organ Transplantation-09 Trial was a randomized, prospec

112 ated factors (hospital with <800 beds, solid organ transplantation activity, higher annual incidence

113 rrent immunosuppressive therapies applied to organ transplantations affect the wide array of Treg pop

114 Organ transplantation after cardiopulmonary resuscitatio

115 Pregnancy after solid organ transplantation, although considered high risk for

116 ew discusses the nature of these triggers in organ transplantation and also potential mediators that

117 of specialized health care services such as organ transplantation and bariatric surgery is advocated

118 f a complex diagnosis especially after solid organ transplantation and can lead to difficulties in fi

119 l stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (proper

120 rus (CMV) is the most common infection after organ transplantation and has a major impact on morbidit

121 imilar to those usually reported after solid organ transplantation and have prompted different strate

122 the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell transp

123 about the T cell response because it governs organ transplantation and hinders the discovery of disea

124 immunocompromised patients, in particular in organ transplantation and in stem cell therapy.

125 er used worldwide to evaluate the success of organ transplantation and is especially feasible after r

126 are common and may lead to a need for solid-organ transplantation and may also contribute to signifi

127 periocular region represents a risk of solid organ transplantation and may produce significant ocular

128 The disparity between patients awaiting organ transplantation and organ availability increases e

129 nhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40

130 therapies to modulate the immune response in organ transplantation and repair tissues after acute or

131 The demand for organ transplantation and repair, coupled with a shortag

132 iciency virus (HIV)-positive persons seeking organ transplantation and serving as organ donors for HI

133 VCA retrieval and transplantation is akin to organ transplantation and should be incorporated into th

134 to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of malig

135 ption of a pathogenic role for NETs in solid organ transplantation and suggest that NETs are a promis

136 65 years are referred for and have access to organ transplantation, and an increasing number of older

137 hma, autoimmune diseases, tumor development, organ transplantation, and chronic infections during the

138 ver disease, lung disease, malignancy, other organ transplantation, and human immunodeficiency virus

139 njury (IRI) is common in general surgery and organ transplantation, and in the case of liver, it trig

140 e rejection remains a significant problem in organ transplantation, and lymphatic and blood vessels a

141 g from smoking cessation and healthy diet to organ transplantation, and most of all condemnation of h

142 irreversible end-stage organ failure undergo organ transplantation, and organs from obese donors are

143 revalent infectious complication after solid organ transplantation, and recipients of isolated intest

144 influenced by cardiovascular disease, other organ transplantation, and the total comorbidity scores.

145 cause of diabetic ketoacidosis, neutropenia, organ transplantation, and/or increased serum levels of

146 Cancer incidence is different among solid organ transplantations, and ratios may be higher than th

147 The Clinical Trials in Organ Transplantation Antibody Core Laboratories investi

148 rms of routine exercise training after solid organ transplantation are unclear.

149 ene (1349/1350 nucleotides), thus confirming organ transplantation as the route of transmission.

150 s, including those for bone marrow and solid organ transplantation, autoimmune diseases, and tissue a

151 opoietic stem cell transplantation, or solid organ transplantation be screened for active or prior he

152 A total of 3489 patients underwent solid organ transplantation between 1990 and 2008.

153 shed with subject headings relating to solid organ transplantation between August 1, 2011, and July 3

154 ompted by the recent completion of the first organ transplantation between HIV-infected persons in Ca

155 nt demonstration of the short term safety of organ transplantation between HIV-infected persons promp

156 is of adult patients who underwent abdominal organ transplantation between January 1, 2008, and Decem

157 t public health measures associated with the organ transplantation, beyond those already in place.

158 ed with morbidity and mortality in abdominal organ transplantation but has not been examined in lung

159 In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)-based

160 Women with a history of solid-organ transplantation can be safely offered a wide range

161 Although desensitization for organ transplantation carries an increased risk of antib

162 The study was conducted in a large organ transplantation center that serves the entire Norw

163 ons in the treatment of autoimmune diseases, organ transplantation, chronic infection, and cancer.

164 llergy, asthma, autoimmune diseases, tumors, organ transplantation, chronic infections, and pregnancy

165 ed for randomized controlled trials in solid organ transplantation comparing an mTOR-I with a non-mTO

166 reatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug resistan

167 wever, the number of patients awaiting solid organ transplantation continues to remain much higher th

168 undergoing immunosuppression following solid organ transplantation, contributing substantially to mor

169 itioning for tolerance induction until after organ transplantation could further decrease the efficac

170 pported by the NIH-funded Clinical Trials in Organ Transplantation (CTOT) Consortium.

171 withdrawal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studies.

172 at led to the multicenter Clinical Trials in Organ Transplantation (CTOT-04) study and the discovery

173 sepsis (CV = 1.37) and among the lowest for organ transplantation (CV </= 0.43).

174 PTLD or chronic high viral loads after solid organ transplantation exhibited no homogeneous EBV gene

175 T cell depletion is commonly used in organ transplantation for immunosuppression; however, a

176 Cell therapies are potential alternatives to organ transplantation for liver failure or dysfunction b

177 ions on necessary future studies to optimize organ transplantation for older people.

178 tely, will not consider manuscripts on human organ transplantation for publication unless appropriate

179 t common infectious complication after solid organ transplantation, frequently affecting the gastroin

180 Organ transplantation from ABO blood group-incompatible

181 Existing legislation allows organ transplantation from an HIV-infected donor under e

182 y review considerations related to advancing organ transplantation from HIV-infected donors in Canada

183 em cell transplant cohort and excluded solid-organ transplantation from this cohort.

184 HIV-infected persons undergoing organ transplantation generally achieve comparable patie

185 The Saudi Center for Organ Transplantation has been established in 1985 as a

186 Their role in organ transplantation has been poorly defined due to con

187 The risk of SCC after organ transplantation has declined significantly since t

188 Emerging knowledge regarding B cells in organ transplantation has demonstrated that these cells

189 gh short-term allograft survival after solid organ transplantation has improved during the past two d

190 biomarkers of acute rejection (AR) in solid organ transplantation have been addressed in multiple sm

191 mechanisms of colorectal carcinoma in solid organ transplantation have not been well characterized.

192 Current immunosuppression regimens for solid-organ transplantation have shown disappointing efficacy

193 is exceptionally high for all patients after organ transplantation; however, predictors of the HRQoL

194 ntibody can be a major barrier to successful organ transplantation; however, therapy to control antib

195 se of a novel procedure called ischemia-free organ transplantation (IFOT) for patients with end-stage

196 After solid organ transplantation, immune-mediated rejection mandate

197 cytomegalovirus (CMV) management after solid organ transplantation in 2010, which provide recommendat

198 e oral cavity, which may develop after solid organ transplantation in children.

199 he National Institutes of Health (NIH) Solid Organ Transplantation in HIV Trial, reflecting experienc

200 ent of India has established laws to conduct organ transplantation in India.

201 cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between 1991 a

202 produced functional bioengineered livers for organ transplantation in preclinical studies.

203 Organ transplantation in the KSA has made great strides

204 n, introduced in 2013, will further increase organ transplantation in the UK.

205 donor-derived HTLV-1-associated death after organ transplantation in the world.

206 T-cell responses occurring in mismatched HLA organ transplantation in which the drug in effect create

207 treatment may improve recipient outcomes in organ transplantation; in this analysis, we aimed to det

208 numerous immunomodulatory therapies used in organ transplantation, including depletional antibody in

209 Studies in other solid-organ transplantations indicate that low levels of serum

210 significant source of late graft loss after organ transplantation.Induction of mixed hematopoietic c

211 one of immunosuppressive therapy after solid organ transplantation, inhibits calcineurin activation.

212 Organ transplantation into sensitized patients with pree

213 Solid organ transplantation is a curative therapy for hundreds

214 The high risk of skin cancer after organ transplantation is a major clinical challenge and

215 ndary to infectious aortitis following solid organ transplantation is a rare event that in the absenc

216 Immunosuppression therapy following organ transplantation is a significant factor in the dev

217 Organ transplantation is a victim of its own success.

218 Solid organ transplantation is a vital therapy for end stage d

219 Although organ transplantation is an effective therapy for older

220 Organ transplantation is an eminent case in which the ev

221 Cytomegalovirus (CMV) infection in solid-organ transplantation is associated with increased morbi

222 Acute kidney injury after nonrenal solid organ transplantation is associated with prolonged lengt

223 ocyte antigen (HLA) class I antibodies after organ transplantation is associated with subsequent acut

224 Solid organ transplantation is encumbered by an increasing num

225 Its use as an induction therapy in organ transplantation is increasing.

226 but the role of the innate immune system in organ transplantation is just emerging.

227 -stage chronic kidney disease, the option of organ transplantation is limited because of the scarce a

228 ABO-incompatible (ABOi) organ transplantation is performed owing to unremitting

229 Saudi Center for Organ Transplantation is playing a central role in all a

230 The role of natural killer (NK) cells in organ transplantation is poorly understood because studi

231 Organ transplantation is the most successful treatment f

232 Solid organ transplantation is the preferred treatment for pat

233 The field of solid organ transplantation is unique in the breadth of the st

234 of generic immunosuppressive drugs in solid organ transplantation is warranted.

235 wine influenza could be transmitted by solid organ transplantation led to the publication of guidance

236 Following organ transplantation, lifelong immunosuppressive therap

237 Severe B-lineage PTLD after solid organ transplantation may be classified as SR or HR and

238 xperience in developing the laws that govern organ transplantation may be of value for others underta

239 plotype B from viral replication after solid organ transplantation may extend beyond CMV to other her

240 eting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took place in B

241 loning will bring enhanced possibilities for organ transplantation, nerve cells and tissue healing, a

242 chronic kidney disease after nonrenal solid organ transplantation (NRSOT), although there are little

243 ing strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host disea

244 an important opportunistic pathogen in solid organ transplantation, particularly in lung transplant r

245 erum samples obtained from nonselected solid-organ transplantation patients suffering from probable,

246 support exclusion of pulmonary IFI in solid-organ transplantation patients, the low positive predict

247 Current immunosuppression regimens in organ transplantation primarily inhibit T cells.

248 In solid organ transplantation recipients, exercise is able to im

249 have reported EBV(-) PTLD in pediatric solid-organ transplantation recipients.

250 Solid organ transplantation reduces both morbidity and mortali

251 We used the Dutch Organ Transplantation Registry to include recipients (>/

252 From the Dutch Organ Transplantation Registry, we selected 3597 recipie

253 Mitigating therapies, aside from impractical organ transplantation, remain limited and the possibilit

254 e relationship of CTLA4Ig and IDO in in vivo organ transplantation remains unclear.

255 ne of the most common infections after solid-organ transplantation, resulting in significant morbidit

256 Organ transplantation results in the activation of both

257 valuation in autoimmune and allogeneic solid organ transplantation settings, data supporting the immu

258 In most solid organ transplantation settings, the role of NK cells is

259 preclinical models and experiences in human organ transplantation should allow for optimization of t

260 acteristics, and outcomes of SAB after solid organ transplantation (SOT) and compare these features w

261 Immune measurements that distinguish solid organ transplantation (SOT) recipients who control cytom

262 tion is an ongoing clinical problem in solid-organ transplantation (SOT).

263 nd mortality among patients undergoing solid organ transplantation (SOT).

264 e net state of immunosuppression after solid organ transplantation (SOT).

265 poieitc cell transplantation (HCT) and solid organ transplantation (SOT).

266 ors, in regulating the alloresponse to solid organ transplantation (SOT).

267 Incidences may vary among solid organ transplantations (SOTs) and may take to particular

268 Organ transplantation started in the Kingdom of Saudi Ar

269 sion as part of the NIAID Clinical Trials in Organ Transplantation Study.

270 and infectious challenges accompanying solid organ transplantation, susceptibility to post-transplant

271 icle, we will consider some of the topics in organ transplantation that were discussed by the attende

272 out hematologic malignancy or previous solid organ transplantation) that were collected for routine m

273 In organ transplantation, the composition of the B-cell com

274 prevalence of diabetes mellitus, cancer, and organ transplantation, the number of patients at risk fo

275 ch are similar to those reported after solid organ transplantation, the patient is satisfied of her n

276 s of rabies virus transmission through solid organ transplantation, there was a long incubation perio

277 KS can develop following organ transplantation through reactivation of the recipi

278 bservation, we sought to model neonatal ABOi organ transplantation to allow mechanistic studies of to

279 extensively by investigators in the field of organ transplantation to study the rejection process, te

280 rdiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss.

281 ve helped to shape the ethical boundaries of organ transplantation today.

282 In experimental organ transplantation, tolerance is induced by administr

283 icity because of congenital and blood and/or organ transplantation transmissions and the reactivation

284 IRI) can occur in clinical scenarios such as organ transplantation, trauma and cardio-pulmonary bypas

285 s in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and

286 ABO-incompatible organ transplantation typically induces hyperacute rejec

287 on-based cancer cohort, we evaluated whether organ transplantation was associated with worse prognosi

288 The SMR for cancer death after solid-organ transplantation was higher in children (SMR, 84.61

289 Solid-organ transplantation was identified using the national

290 ccurring in a kidney recipient shortly after organ transplantation was identified.

291 In previous decades, access to organ transplantation was restricted to academic medical

292 The relevance of this pathway to solid-organ transplantation was then confirmed by the demonstr

293 n, haematological malignancies, and previous organ transplantation were excluded).

294 xciting advances in the clinical sciences in organ transplantation were presented at the American Tra

295 Unlike solid organ transplantation, which is potentially life-saving,

296 Balamuthia can be transmitted through organ transplantation with an observed incubation time o

297 ow) regulatory T cells (Tregs) in a model of organ transplantation with CD40Ig could be abrogated by

298 and everolimus, are increasingly used after organ transplantation with potential advantages in virus

299 Seventy-four cases of PTLD after solid organ transplantation with sufficient material for furth

300 virus (HTLV)-1 has been reported after solid-organ transplantation, with a related fatal outcome in l